Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease | MicrobiomeTrials← Back to trialsNCT07123350
Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease
RecruitingOBSERVATIONAL
Trial Details
Start: 2025-10-16Est. Completion: 2026-03-31
Enrollment target: 120 participants Locations- Vanderbilt University Medical Center, Nashville, Tennessee, United States
Other microbiome trials you might be interested in
Inflammatory Bowel DiseaseCrohn's DiseaseUlcerative Colitis
Background:
Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in …
Bethesda, United StatesEst. completion Jun 1, 2036
Gastrointestinal Disease Symptoms
The aim of this study is to determine how regular consumption of Synbiotic+, a dietary supplement that contains prebioti…
Fort Collins, United StatesCompleted Aug 1, 2026
Recruiting
Inflammatory Bowel Disease (IBD)
This observational study will use intestinal ultrasound images to help develop computer programs that may make it easier…
Vancouver, CanadaEst. completion Feb 1, 2027